Pharmacovigilance Market : Drivers, Challenges, Historical and current Sizes (2015 - 2020)

Future Market Insights offers a 6-year forecast of the global pharmacovigilance market between 2015 and 2020. In terms of value, the market is expand at a CAGR of 14.2% during the forecast period. This study demonstrates market dynamics and trends in all seven regions that are expected to influence the current environment and future status of the pharmacovigilance market over the forecast period.

Report Description

This Future Market Insights report examines the pharmacovigilance market for the period 2015-2020. The primary objective of the report is to offer insights into developments in the pharmacovigilance market that are significantly transforming global businesses and enterprises.

The global pharmacovigilance market report begins by defining pharmacovigilance and its various segments. This is followed by an overview of the global pharmacovigilance market. The overview section includes FMI analysis of key trends, drivers, restraints, trends and opportunities that are influencing growth of the pharmacovigilance market currently. It also includes information related to the market shares of the major players in the market. Impact analyses of key growth drivers and restraints based on the weighted average model have been included in this report on the global pharmacovigilance market to better equip customers and readers with region specific trends and insights.

The primary driving factor for growth of the pharmacovigilance market is the significant increase witnessed in the intake of medical drugs. Besides, increase in prevalence of acute and chronic diseases has consequently led to an increase in incidences of drug consumption, thereby leading to a rise in the number of adverse drug events and drug toxicity cases. This, in turn, has triggered the growth of the pharmacovigilance market globally. Furthermore, safety regulations, risk of high-profile safety issues and need to review large volume of post-market events along with negative media coverage have compelled the pharmaceutical players to take support of various outsourcing services for drug monitoring. Factors such as intensifying regulatory expectations, tougher inspection system and instant need for patient reporting are boosting the adoption rate of pharmacovigilance among pharmaceutical companies globally. Pharmaceutical companies are now entering into long-term partnerships/service agreements with CROs and BPOs to reduce the pharmacovigilance process related expenditure, incurred right from drug discovery to post-marketing approvals.

Read Complete Report @ http://www.mrrse.com/pharmacovigilance-market

The global pharmacovigilance market is segmented based on phase of drug development, type of reporting methods and type of service providers. On the basis of phase of drug development, the market has been segmented into preclinical studies, phase I clinical trial, phase II clinical trial, phase III clinical trial and phase IV clinical trial or post-marketing surveillance. On the basis of type of reporting methods, the market has been segmented into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, cohort event monitoring and EHR mining. On the basis of the type of service providers, the market has been segmented into in-house and contract outsourcing. A detailed analysis has been provided for all segments and sub-segments in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

A deep market analysis along with market attractiveness index for each of the categories have been provided in the report. The next section of the report highlights the pharmacovigilance market by region. It provides a market outlook for 2015–2020 and sets the forecast within the context of the pharmacovigilance market. The study discusses key regional trends contributing to growth of the pharmacovigilance market worldwide, as well as analyses the extent to which the drivers are influencing this market in each region. Key regions assessed in this report include North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan and the Middle East & Africa.

The above sections, by phase of drug development, type of reporting methods and type of service providers and region, evaluate the present scenario and growth prospects of the pharmacovigilance market for the period 2015 –2020. We have considered 2014 as the base year and provided data for the forecast period, i.e. 2015–2020.

Enquiry For This Report @ http://www.mrrse.com/enquiry/1472

To ascertain the market size of pharmacovigilance, we have also considered revenue generated by pharmacovigilance companies. The forecast presented here assesses the total revenue generated across the pharmacovigilance market. In order to offer an accurate forecast, we started by sizing the current market, which forms the basis of how the pharmacovigilance market is expected to develop in the future. Given the characteristics of the market, we triangulated the outcome of three different types of analysis, based on supply side, downstream industry demand and the economic envelope.

In addition, it is imperative to note that in an ever-fluctuating global economy, we not only conduct forecasts in terms of CAGR, but also analyse the market based on key parameters, such as Year-on-Year (Y-o-Y) growth rates, to understand the predictability of the market and to identify the right growth opportunities in the market.

In this report, the pharmacovigilance market is segmented in terms of phase of drug development, type of reporting methods, type of service providers and region. These segments are analysed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identification of various key trends in the pharmacovigilance market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the pharmacovigilance market.

To understand key growth segments in terms of growth across the globe in the near future, Future Market Insights developed the pharmacovigilance market attractiveness index. The resulting index should help providers identify real market opportunities.

In the final section of the report, the ‘Competitive Landscape’ of the market is included to provide report audiences with a dashboard view, based on categories of providers in the value chain of the pharmacovigilance product portfolio and key differentiators. Key categories of providers covered in the report are pharmacovigilance companies. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment of the pharmacovigilance value chain and the potential players with respect to the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on their in-depth assessment of capabilities and successes in the pharmacovigilance marketplace.

Detailed profiles of the pharmacovigilance companies are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments. Key players included in the report are Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), ICON plc, iGATE Corporation, iMEDGlobal Corporation, inVentiv Health, Inc., Novartis International AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), PRA Health Sciences, Inc., Quintiles Transnational Holdings, Inc., Sanofi S.A., Synowledge LLC and Wipro Limited.

Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1472

Key Segments Covered

By Phases of Drug Development

Preclinical Studies
Phase I
Phase II
Phase III
Phase IV or Post Marketing Surveillance
By Type of Method

Spontaneous Reporting
Intensified ADR Reporting
Targeted Spontaneous Reporting
Cohort Event Monitoring
EHR Mining

By Type of Service Provider

In-house Pharmacovigilance
Contract Outsourcing

Key Regions/Countries Covered

North America
U.S.
Canada

Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Western Europe
U.K.
France
Germany
Spain
Italy
Nordics
BENELUX
Rest of Western Europe

Eastern Europe
Poland
Russia
Rest of Eastern Europe

Asia Pacific Excluding Japan (APEJ)
Greater China
India
ASEAN
Australia and New Zealand
Rest of APEJ

Japan

Middle East & Africa

GCC
South Africa
Rest of MEA

Key Companies

Accenture plc
Bristol-Myers Squibb
Clinquest Group B.V.
Cognizant Technology Solutions
Covance, Inc.
Hoffmann-La Roche Ltd.
GlaxoSmithKline plc (GSK)
ICON plc
iGATE Corporation
iMEDGlobal Corporation
inVentiv Health, Inc.
Novartis International AG
PAREXEL International Corporation
Pfizer, Inc.
Pharmaceutical Product Development, LLC. (PPD)
PRA Health Sciences, Inc.
Quintiles Transnational Holdings, Inc.
Sanofi A.
Synowledge LLC
Wipro Limited

Table of Content

1 Introduction

1.1 Report Description

1.2 Research Methodology

1.3 Market Segmentation

2 Executive Summary

About MRRSE

MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Corporate Office State Tower 90 State Street, Suite 700 Albany, NY 12207,United States

This release was published on openPR.